Web Content Viewer
Actions
Newborn Screening
Newborn Screening
Newborn Screening
Only five drops of a baby’s blood are needed to identify babies at risk for many serious medical conditions. If left untreated, these conditions can lead to slow growth, developmental disabilities, and possible death. Identifying these conditions early and providing appropriate treatment may prevent serious complications.

Newborn screening can save a baby’s life!


Only five drops of a baby’s blood are needed to identify babies at risk for many serious medical conditions. If left untreated, these conditions can lead to slow growth, developmental disabilities, and possible death. Identifying these conditions early and providing appropriate treatment may prevent serious complications.

The Ohio Newborn screening Program also provides funding to pediatric specialty clinics that diagnose and treat babies affected by these conditions. Metabolic formula for treating conditions such as phenylketonuria (PKU) and homocystinuria are available through the Ohio Department of Health (ODH) Metabolic Formula Program.

 
Ohio newborns are also screened for congenital hearing loss and critical congenital heart disease. For more information about screening for these conditions click the links below.

Ohio Infant Hearing Program

Critical Congenital Heart Disease

OSU Presentations:

Teams of undergraduate students majoring in Biochemistry at The Ohio State University (OSU), Columbus, OH were tasked with producing a presentation that describes in lay terms some of the human disorders that are now part of the Newborn Screening program conducted by the Ohio Department of Health (ODH). Presentations for the following disorders are included: Argininemia, Krabbe Leukodystrophy, and Propionic Acidemia. A disorder not currently screened by ODH, Ornithine transcarbamylase, is also included.
For the disease selected by each team, they were expected to cover: (i) History; (ii) Occurrence, provenance, and genetics; (iii) Biochemical feature(s); (iv) Symptom(s); (v) Diagnosis; (vi) Prognosis; and (vii) Therapy. Each team comprised of nine students enrolled in Biochemistry 5614 (Autumn 2018 offering) and had one lead person for text and one lead person for illustrations. All team members contributed to the overall presentation now being shared as part of the Ohio Newborn Screening Program. Dr. Venkat Gopalan (Course Instructor, Biochemistry 5614) led and provided oversight for the entire project. Dr. Karl Roth (Visiting Scholar, Dept. of Chemistry & Biochemistry) and members of the ODH Laboratory Newborn Screening Program have evaluated these presentations for clinical content and scope.
Link to OSU’s knowledge bank: OSU Undergraduate Presentations
 

For more information about Newborn Screening Program for Genetic, Endocrine, and Metabolic Conditions contact the Public Health Laboratory.